Cardiology in review
-
Cardiology in review · Jan 2014
ReviewNew antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Obesity is a risk factor for a wide range of conditions, including cardiovascular disease. Although lifestyle modifications remain the cornerstone for the management of obesity, pharmacologic agents may be a helpful addition to patients who have comorbidities and do not respond adequately to diet and exercise. ⋯ This article reviews the pharmacology and clinical efficacy and safety of each of these agents. The differences among the three available agents for long-term management of obesity will also be examined.